Follow
Sanghavi Kinjal
Sanghavi Kinjal
Genmab US
No verified email
Title
Cited by
Cited by
Year
Genomewide association study of tacrolimus concentrations in African American kidney transplant recipients identifies multiple CYP3A5 alleles
WS Oetting, DP Schladt, W Guan, MB Miller, RP Remmel, C Dorr, ...
American Journal of Transplantation 16 (2), 574-582, 2016
1272016
Clinical pharmacology considerations for the development of immune checkpoint inhibitors
J Sheng, S Srivastava, K Sanghavi, Z Lu, BJ Schmidt, A Bello, M Gupta
The Journal of Clinical Pharmacology 57, S26-S42, 2017
1152017
PharmGKB summary: mycophenolic acid pathway
V Lamba, K Sangkuhl, K Sanghavi, A Fish, RB Altman, TE Klein
Pharmacogenetics and genomics 24 (1), 73-79, 2014
802014
Genotype-guided tacrolimus dosing in African-American kidney transplant recipients
K Sanghavi, RC Brundage, MB Miller, DP Schladt, AK Israni, W Guan, ...
The pharmacogenomics journal 17 (1), 61-68, 2017
732017
Abstract CT180: Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors
LL Siu, H Burris, DT Le, A Hollebecque, N Steeghs, JP Delord, J Hilton, ...
Cancer Research 78 (13_Supplement), CT180-CT180, 2018
452018
Differentially expressed gene transcripts using RNA sequencing from the blood of immunosuppressed kidney allograft recipients
C Dorr, B Wu, W Guan, A Muthusamy, K Sanghavi, DP Schladt, ...
PloS one 10 (5), e0125045, 2015
312015
Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning
K Sanghavi, A Wiseman, MN Kirstein, Q Cao, R Brundage, K Jensen, ...
Translational Research 175, 103-115. e4, 2016
302016
Population pharmacokinetics of ipilimumab in combination with nivolumab in patients with advanced solid tumors
K Sanghavi, J Zhang, X Zhao, Y Feng, P Statkevich, J Sheng, A Roy, ...
CPT: Pharmacometrics & Systems Pharmacology 9 (1), 29-39, 2020
282020
Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors
S Lorenzen, LL Siu, H Burris, DT Le, A Hollebecque, N Steeghs, ...
272018
Population pharmacokinetics of nivolumab in combination with ipilimumab in patients with advanced malignancies
J Zhang, K Sanghavi, J Shen, X Zhao, Y Feng, P Statkevich, J Sheng, ...
CPT: Pharmacometrics & Systems Pharmacology 8 (12), 962-970, 2019
212019
Reporting, visualization, and modeling of immunogenicity data to assess its impact on pharmacokinetics, efficacy, and safety of monoclonal antibodies
C Passey, S Suryawanshi, K Sanghavi, M Gupta
The AAPS Journal 20, 1-13, 2018
122018
Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment
A Blaes, D Duprez, T Defor, R Shanley, H Beckwith, T Haddad, D Potter, ...
Springerplus 4, 1-7, 2015
112015
Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion
AF Alharbi, RA Kratzke, J D’Cunha, MA Maddaus, K Sanghavi, ...
Cancer chemotherapy and pharmacology 83, 387-391, 2019
72019
BMS-986012, an Anti–fucosyl-GM1 monoclonal antibody as monotherapy or in combination with nivolumab in relapsed/refractory SCLC: results from a first-in-human phase 1/2 study
Q Chu, NB Leighl, V Surmont, C van Herpen, A Sibille, B Markman, ...
JTO Clinical and Research Reports 3 (11), 100400, 2022
62022
Higher fludarabine and cyclophosphamide exposures lead to worse outcomes in reduced-intensity conditioning hematopoietic cell transplantation for adult hematologic malignancy
T Takahashi, A Scheibner, Q Cao, R Pearson, K Sanghavi, DJ Weisdorf, ...
Transplantation and cellular therapy 27 (9), 773. e1-773. e8, 2021
52021
CheckMate 8KX: Phase 1/2 multitumor preliminary analyses of a subcutaneous formulation of nivolumab (ħrHuPH20).
S Lonardi, I Lugowska, CGCA Jackson, A O'Donnell, R Bahleda, ...
Journal of Clinical Oncology 39 (15_suppl), 2575-2575, 2021
52021
Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma
T Ide, M Osawa, K Sanghavi, HE Vezina
Cancer Chemotherapy and Pharmacology 89 (1), 129-140, 2022
32022
Nivolumab exposure–response analysis for adjuvant treatment of melanoma supporting a change in posology
K Sanghavi, P Vuppala, V Ivaturi, L Hamuro, A Roy, S Suryawanshi
CPT: Pharmacometrics & Systems Pharmacology 10 (7), 748-759, 2021
32021
Variants associated with tacrolimus troughs in European American kidney transplant recipients: A genome wide association study
P Jacobson, M Miller, D Schladt, A Israni, K Sanghavi, C Dorr, R Remmel, ...
American Journal of Transplantation 15, 2015
32015
Effects of cyclophosphamide related genetic variants on clinical outcomes of adult hematopoietic cell transplant patients
T Takahashi, R Pearson, Q Cao, A Scheibner, K Sanghavi, D Weisdorf, ...
Cancer chemotherapy and pharmacology 89 (4), 543-549, 2022
22022
The system can't perform the operation now. Try again later.
Articles 1–20